home / stock / nvs / nvs articles

NVS Articles, Novartis AG - From 04/09/24

Stock Information
Company Name: Novartis AG
Stock Symbol: NVS
Market: NYSE
Website: novartis.com
Menu
NVS NVS Quote NVS Short NVS News NVS Articles NVS Message Board
Get NVS Alerts

News, Short Squeeze, Breakout and More Instantly...
Enliven Therapeutics Well-Positioned, With Conservative Trading Levels-Analyst Says | Benzinga

Mizuho Securities initiated coverage on Enliven Therapeutics Inc (NASDAQ:ELVN), a clinical-stage precision oncology company focused ...
Novartis To Axe 680 Development Jobs Amid Global Reshuffle: Report | Benzinga

Novartis AG (NYSE:NVS) reportedly plans to slash up to 680 positions in its development organization, aiding in drug market launches. The...

Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider Population | Benzinga

Friday, the FDA approved Johnson & Johnson (NYSE:JNJ) Carvykti (ciltacabtagene autoleucel; cilta-cel) for relapsed or refractory mult...

Why Is Novartis Stock Trading Higher On Thursday? | Benzinga

Thursday, Novartis AG (NYSE:NVS) shares are trading higher after the company confirmed plans to file for Pluvicto pre-taxane la...
Magnificent 7 Stocks Become The Star Attractions For Norway's Sovereign Wealth Fund | Benzinga

If anyone needs any proof of how the landscape of investment has changed as a result of a handful of technology companies over the past decade, tak...

Ozempic Users Speak Out Over Side Effects, Lawsuits Against Novo Nordisk And Eli Lilly Surge | Benzinga

Scores of patients are reportedly taking legal action against pharmaceutical giants Eli Lilly And Co (NYSE:LLY) and Novo Nordisk A/S...

GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy | Benzinga

Key Takeaways: GenScript’s cell therapy revenue grew by 143.7% last year as a CAR-T cell therapy developed by its Legend Biotech subsidiary ...
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform | Benzinga

H.C. Wainwright initiated coverage on Voyager Therapeutics Inc (NASDAQ:VYGR), noting a growing franchise of novel, highly-differenti...

FDA Approves BeiGene's First Drug Candidate Produced Through Its Immuno-Oncology Program For Esophageal Cancer | Benzinga

On Thursday, the FDA approved BeiGene Ltd’s (NASDAQ:BGNE) approved Tevimbra (tislelizumab-jsgr) as monotherapy for adult patients w...

Medicare's Ambitious Drug Price Negotiation Plan: President Joe Biden Calls To Expand Targeted Medicines To 50 Annually by 2029 | Benzinga

In a move outlined in his upcoming State of the Union address, President Joe Biden is pushing for an increase in the number of prescripti...
Previous 10 Next 10